Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2021-06-15

Product name:

RETEVMO

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02516918

Product Monograph/Veterinary Labelling:

Date: 2021-06-11 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

LOXO ONCOLOGY INC
FL 9  281 Tresser Blvd
Stamford
Connecticut
United States  06901

Class: 

Human

Dosage form(s):

Capsule

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription  

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00   ANTINEOPLASTIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01XE  PROTEIN KINASE INHIBITORS

Active ingredient group (AIG) number:See footnote 5

0162988001

List of active ingredient(s)
Active ingredient(s) Strength
SELPERCATINIB 40 MG

Application information

Related information

Contact us

Version 3.9.1
Date modified: